Lovende COVID-19 behandling sender aktier 3% op

Uddrag fra tidsskriftet STAT-  læs hele artiklen

AChicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.
Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests.The entire world has been waiting for results from Gilead’s clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies.
If safe and effective, it could become the first approved treatment against the disease.The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those people, 113 had severe disease. All the patients have been treated with daily infusions of remdesivir.
Læs også:  Vækstfaldet i den globale økonomi flader nu ud

 

Skriv en kommentar

Please enter your comment!
Indtast dit navn her